Cancer Topics - Recent Approvals: Erdafitinib and Enfortumab for Second-Line Treatment of Metastatic Bladder Cancer

Dr. Winston Tan, Medical Oncologist at Mayo Clinic, discusses the recent FDA approval of erdafitinib and enfortumab for second-line treatment of metastatic bladder cancer.

Episode metadata supplied by the publisher feed · Published Feb 12, 2020

Embed this episode

Attribution link and audio player

NOW PLAYING

Cancer Topics - Recent Approvals: Erdafitinib and Enfortumab for Second-Line Treatment of Metastatic Bladder Cancer

0:00 5:39

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of ASCO Education?

This episode is 5 minutes long.

When was this ASCO Education episode published?

This episode was published on February 12, 2020.

Can I download this ASCO Education episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!